Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Merck Sharp & Dohme LLC
Age
18–any
Sex
MALE
Healthy volunteers
Accepted
You may be eligible if
All participants:
Is a continuous non-smoker or moderate smoker (≤ 10 cigarettes per day or equivalent) for at least 3 months prior to dosing
Has body mass index (BMI) ≥ 18.0 and ≤ 42.0 kg/m2
Participants with moderate hepatic impairment:
Has a diagnosis of chronic, stable, hepatic insufficiency with features of cirrhosis due to any etiology
You may not be if
All participants:
Has a first-degree relative with multiple unexplained syncopal events, unexplained cardiac arrest, or sudden cardiac death, or has a known family history of an inherited arrhythmia syndrome (including Brugada syndrome)
Has a history of cancer (malignancy)
Has positive results for human immunodeficiency virus (HIV), hepatitis B virus (HBV), or hepatitis C virus (HCV)
Participants with moderate hepatic impairment
Has unstable electrolyte abnormalities or electrolyte abnormalities that are considered difficult to manage for participants with hepatic impairment
Has a history of liver or other solid organ transplantation
Clareo Health | A Study to Evaluate Opevesostat (MK-5684) in Male Participants With Moderate Hepatic Impairment (MK-5684-009)
